Samsung plans to bring this early cancer detection test to Asia

Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL have signed a deal to bring GRAIL’s Galleri multi-cancer early detection (MCED) test to key Asian markets. Initially, they will offer the test in South Korea, and later, if possible, in Japan and Singapore.

GRAIL is an American biotechnology company and is focused on developing tests for early cancer detection. GRAIL’s latest deal with SCT and SEC will help people in the three countries detect cancer in early stages, which will increase their chances of beating it.

Along with that, SCT and SEC have agreed to invest $110 million in GRAIL at a stock price of $70.05. Samsung C&T also says that undertake key activities to drive the adoption of Galleri across these regions.

Commenting on the deal, SCT’s Executive Vice President of Life Science Business, Jaywoo Kim, said, “Guided by its commitment to advancing next-generation bio-technologies and improving quality of life, Samsung C&T has continuously invested in innovative companies. The collaboration with GRAIL represents a significant new step—moving beyond investment to a strategic business partnership that provides Samsung with a strong foothold for expanding into the cancer screening field and delivering one of these promising technologies to customers in South Korea and across Asia.”

On the other hand, GRAIL’s President of International Business & Biopharma, Sir Harpal Kumar, said, “We look forward to partnering with Samsung to bring multi-cancer early detection to Asia, beginning in South Korea. Samsung’s significant equity investment strengthens our balance sheet and provides further cash runway as we advance through key milestones to secure reimbursement for Galleri in the U.S. and key international markets.”